Molecular Templates Stock (NASDAQ:MTEM)


RevenueOwnershipFinancialsChart

Previous Close

$0.16

52W Range

$0.13 - $4.12

50D Avg

$0.46

200D Avg

$1.27

Market Cap

$921.74K

Avg Vol (3M)

$14.93M

Beta

1.22

Div Yield

-

MTEM Company Profile


Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

62

IPO Date

Feb 04, 2005

Website

MTEM Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 22Dec 21Dec 20
Research And Development Related Party-$13.14M-
Research And Development Other$19.75M$25.56M-
Grant--$3.21M

Fiscal year ends in Dec 23 | Currency in USD

MTEM Financial Summary


Dec 23Dec 22Dec 21
Revenue$57.31M$19.75M$38.70M
Operating Income$-10.47M$-88.87M$-80.07M
Net Income$-8.12M$-92.72M$-79.31M
EBITDA$-3.56M$-87.88M$-80.07M
Basic EPS$-1.80$-24.69$-21.51
Diluted EPS$-1.80$-24.69$-21.51

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
IPSCCentury Therapeutics, Inc.
ERASErasca, Inc.
SRZNSurrozen, Inc.
NUVBNuvation Bio Inc.
VCNXVaccinex, Inc.
MNPRMonopar Therapeutics Inc.
IKNAIkena Oncology, Inc.
MLYSMineralys Therapeutics, Inc.
CTMXCytomX Therapeutics, Inc.
ASMBAssembly Biosciences, Inc.
RNXTRenovoRx, Inc.
TPSTTempest Therapeutics, Inc.
KZRKezar Life Sciences, Inc.
FBRXForte Biosciences, Inc.
TILInstil Bio, Inc.
NKTXNkarta, Inc.
TARAProtara Therapeutics, Inc.